Day: July 10, 2022

Figure 1 Change in FVC Over 12 Weeks in INTEGRIS-IPF; Mixed Model Repeat Measures Analysis – Intent to Treat PopulationFigure 2 Proportion of Participants with FVCpp Decline ≥10% – Intent to Treat PopulationPLN-74809 demonstrated a dose-dependent treatment effect on FVC and QLF versus placebo over 12 weeks of treatment PLN-74809 treatment effect was observed on top of standard of care therapy and as monotherapy PLN-74809 was well tolerated over 12 weeks of treatment with no drug related SAEs and no treatment discontinuations due to adverse events Company to host webcast and conference call tomorrow, Monday July 11 at 8:00 a.m. ET SOUTH SAN FRANCISCO, Calif., July 10, 2022 (GLOBE NEWSWIRE) — Pliant Therapeutics, Inc. (Nasdaq: PLRX), today announced positive data from INTEGRIS-IPF, a multinational, randomized, double-blind,...

Company announcement no 10 2022  Danske Bank A/SHolmens Kanal 2 – 12DK – 1092 København KTel. +45 45 14 00 00 10 July 2022Due to challenging financial market conditions, Danske Bank A/S revises 2022 net profit outlook downwards despite a positive development for core banking activities. Now expects a net profit of DKK 10-12 billion The outlook for 2022 is revised downwards to a net profit in the range of DKK 10-12 billion. At the release of our 2021 financial results on 3 February this year, we initially guided for a full-year 2022 net profit in the range of DKK 13-15 billion subject to normalised financial market conditions. “We have seen good commercial progress in our core banking activities in the first half of the year driven by volume growth, solid customer activity and a continued solid credit quality. Our core income...

Data presented today show a reduction in treated spontaneous and traumatic bleeds and mean annualised bleeding rate (ABR) of 1.7 with concizumab1 London, UK, 10 July 2022 – Novo Nordisk announced the phase 3 results of the explorer7 study, assessing the efficacy and safety of prophylactic treatment with concizumab in people living with haemophilia A or B with inhibitors.1 The results from the primary analysis were presented today at the International Society of Thrombosis and Haemostasis Annual Congress (ISTH 2022) in London, UK. Concizumab is an anti-tissue factor pathway inhibitor (TFPI) antibody in development for once-daily prophylactic treatment (regular treatment to prevent prolonged and spontaneous bleeding) by administration under-the-skin for all types of haemophilia. The use of concizumab is investigational and not approved by...

Fitusiran prophylaxis reduced bleeds by 61% in people with hemophilia A or B, with or without inhibitors, compared to prior factor or bypassing agent prophylaxisA median annualized bleeding rate (ABR) of 0.0 was reported in the overall study population during fitusiran prophylaxis (80 mg monthly) Fitusiran is a novel, investigational subcutaneously administered small interference RNA therapy, in development for the prophylactic treatment of people with hemophilia A or B, with or without inhibitorParis – July 10, 2022 – Positive data from the Phase 3 ATLAS-PPX study evaluating the efficacy and safety of once-monthly fitusiran (80 mg) in adults and adolescents with severe hemophilia A or B who were previously treated with prior factor or bypassing agent (BPA) prophylaxis were presented today in a late-breaking session at the International...

Pivotal data demonstrate once-weekly efanesoctocog alfa provides superior bleed protection compared to prior factor prophylaxisInvestigational once–weekly efanesoctocog alfa prophylaxis met the primary efficacy endpoint providing clinically meaningful bleed protection for people with severe hemophilia A Results underscore the ability of efanesoctocog alfa to sustain normal to near-normal factor levels and the potential to transform prophylactic treatment, providing people with hemophilia A with higher protection for longer Additional data showed efanesoctocog alfa prophylaxis resulted in statistically significant and clinically meaningful improvements in physical health, pain intensity and joint health in patients on prior factor VIII prophylaxisParis and Stockholm – July 10, 2022 – Sanofi and Swedish Orphan Biovitrum AB (publ)...

A candidates name was misprinted in previous announcement. The list is as follows: Ástvaldur Jóhannsson Björgólfur Jóhannsson Guðjón Reynisson Helga Jóhanna Oddsdóttir Herdís Pála Pálsdóttir Hjörleifur Pálsson Magnús Júlíusson Margrét Guðmundsdóttir Óskar Jósefsson Sigrún Hjartardóttir Sigurlína Ingvarsdóttir Viðar Örn Traustason Þórdís Jóna Sigurðardóttir Þórey G. Guðmundsdóttir

All amounts expressed in US dollars NORTH MARA GOLD MINE, Tanzania, July 10, 2022 (GLOBE NEWSWIRE) — Barrick Gold Corporation (NYSE:GOLD)(TSX:ABX) has been recognised as the largest contributor to government revenue in 2021, confirming its position as a key partner in the socio-economic development of Tanzania. President and chief executive Mark Bristow told media here today that since the company took control of North Mara and Bulyanhulu in September 2019, its total in-country investment has totalled $1.995 billion1. In the first half of this year, it has paid $158 million in taxes, royalties and levies, $42 million in distributions to the Government of Tanzania in the form of dividends and shareholder loans as well as $210 million to local suppliers. It has also now paid $140 million of its $300 million settlement with the government. “When...

FLT180a generated protective FIX levels with no bleeding or need for FIX replacement The treatment was well tolerated with a good safety profile LONDON, July 10, 2022 (GLOBE NEWSWIRE) — Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced the presentation of safety and initial efficacy data from the first cohort of the Phase 1/2 dose-confirmation B-LIEVE trial for FLT180a, the company’s AAVS3-based gene therapy candidate for people with hemophilia B, at the International Society on Thrombosis and Haemostasis (ISTH) Congress being held in London, July 9-13, 2022. As of the data cut-off of May 23, 2022, a one-time FLT180a dose of 7.7e11 vg/kg generated a rapid increase of coagulation factor IX (FIX), reaching levels in the normal range (93, 92 and 80 IU/dL) for the three patients in cohort 1 through days 77, 56 and 36,...